TY - JOUR
T1 - The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force
T2 - Findings from the consumer expert Delphi process
AU - Zanker, Jesse
AU - Sim, Marc
AU - Anderson, Kate
AU - Balogun, Saliu
AU - Brennan-Olsen, Sharon L
AU - Dent, Elsa
AU - Duque, Gustavo
AU - Girgis, Christian M
AU - Grossmann, Mathis
AU - Hayes, Alan
AU - Henwood, Tim
AU - Hirani, Vasant
AU - Inderjeeth, Charles
AU - Iuliano, Sandra
AU - Keogh, Justin
AU - Lewis, Joshua R.
AU - Lynch, Gordon S.
AU - Pasco, Julie A.
AU - Phu, Steven
AU - Reijnierse, Esmee M.
AU - Russell, Nicholas
AU - Vlietstra, Lara
AU - Visvanathan, Renuka
AU - Walker, Troy
AU - Waters, Debra L.
AU - Yu, Solomon
AU - Maier, Andrea B.
AU - Daly, Robin M.
AU - Scott, David
N1 - Publisher Copyright:
© 2022 The Authors. Australasian Journal on Ageing published by John Wiley & Sons Australia, Ltd on behalf of AJA Inc’.
PY - 2023/3
Y1 - 2023/3
N2 - Objectives: To develop guidelines, informed by health-care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand. Methods: A three-phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health-care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome priorities, consultation preferences and interventions. Findings were confirmed and disseminated in Phase 3. Descriptive statistical analyses were performed. Results: Twenty-four consumers (mean ± standard deviation age 67.5 ± 12.8 years, 18 women) participated in Phase 2. Ten (42%) identified as being interested in sarcopenia, 7 (29%) were health-care consumers and 6 (25%) self-reported having/believing they have sarcopenia. Consumers identified physical performance, living circumstances, morale, quality of life and social connectedness as the most important outcomes related to sarcopenia. Consumers either had no preference (46%) or preferred their doctor (40%) to diagnose sarcopenia and preferred to undergo assessments at least yearly (54%). For prevention and treatment, 46% of consumers preferred resistance exercise, 2–3 times per week (54%). Conclusions: Consumer preferences reported in this study can inform the implementation of sarcopenia guidelines into clinical practice at local, state and national levels across Australia and New Zealand.
AB - Objectives: To develop guidelines, informed by health-care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand. Methods: A three-phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health-care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome priorities, consultation preferences and interventions. Findings were confirmed and disseminated in Phase 3. Descriptive statistical analyses were performed. Results: Twenty-four consumers (mean ± standard deviation age 67.5 ± 12.8 years, 18 women) participated in Phase 2. Ten (42%) identified as being interested in sarcopenia, 7 (29%) were health-care consumers and 6 (25%) self-reported having/believing they have sarcopenia. Consumers identified physical performance, living circumstances, morale, quality of life and social connectedness as the most important outcomes related to sarcopenia. Consumers either had no preference (46%) or preferred their doctor (40%) to diagnose sarcopenia and preferred to undergo assessments at least yearly (54%). For prevention and treatment, 46% of consumers preferred resistance exercise, 2–3 times per week (54%). Conclusions: Consumer preferences reported in this study can inform the implementation of sarcopenia guidelines into clinical practice at local, state and national levels across Australia and New Zealand.
KW - community-based participatory research
KW - geriatric assessment
KW - sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85144029740&partnerID=8YFLogxK
U2 - 10.1111/ajag.13164
DO - 10.1111/ajag.13164
M3 - Article
SN - 1440-6381
VL - 42
SP - 251
EP - 257
JO - Australasian Journal on Ageing
JF - Australasian Journal on Ageing
IS - 1
ER -